Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Virus or bacteriophage
Reexamination Certificate
2008-11-18
2011-10-25
Lucas, Zachariah (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Virus or bacteriophage
C424S093200, C435S235100, C435S320100
Reexamination Certificate
active
08043612
ABSTRACT:
The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.
REFERENCES:
patent: 4108983 (1978-08-01), Wallack
patent: 5124148 (1992-06-01), Csatary et al.
patent: 5198336 (1993-03-01), Knobeloch et al.
patent: 5215745 (1993-06-01), Csatary et al.
patent: 5273745 (1993-12-01), Schirrmacher
patent: 5274137 (1993-12-01), Nicolaou et al.
patent: 5585096 (1996-12-01), Martuza et al.
patent: 5602023 (1997-02-01), Csatary
patent: 5633274 (1997-05-01), Halperin et al.
patent: 5677178 (1997-10-01), McCormick
patent: 5688773 (1997-11-01), Chiocca et al.
patent: 5698443 (1997-12-01), Henderson et al.
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 6110461 (2000-08-01), Lee et al.
patent: 6136307 (2000-10-01), Lee et al.
patent: 6261555 (2001-07-01), Lee et al.
patent: 6344195 (2002-02-01), Lee et al.
patent: 6551587 (2003-04-01), Hallenbeck et al.
patent: 6638762 (2003-10-01), Chang et al.
patent: 7122182 (2006-10-01), Groene et al.
patent: 39 22 444 (1991-10-01), None
patent: 0 292 293 (1988-11-01), None
patent: 0 292 293 (1988-11-01), None
patent: 0 514 603 (1992-11-01), None
patent: 0 564 121 (1993-10-01), None
patent: 0 583 142 (1994-02-01), None
patent: 0252741 (1997-10-01), None
patent: 1 314 431 (2003-05-01), None
patent: 1069144 (1967-05-01), None
patent: A 58-116422 (1983-07-01), None
patent: 10-5342 (1998-01-01), None
patent: WO 86/00529 (1986-01-01), None
patent: WO 86/00811 (1986-02-01), None
patent: WO 89/07445 (1989-08-01), None
patent: WO 93/18790 (1993-09-01), None
patent: WO 94/16716 (1994-08-01), None
patent: 94/19022 (1994-09-01), None
patent: WO 94/18992 (1994-09-01), None
patent: WO 94/25627 (1994-11-01), None
patent: WO 95/32706 (1995-12-01), None
patent: WO 96/00007 (1996-01-01), None
patent: WO 96/03997 (1996-02-01), None
patent: 96/16676 (1996-06-01), None
patent: 96/17053 (1996-06-01), None
patent: 96/26285 (1996-08-01), None
patent: 96/34625 (1996-11-01), None
patent: WO 97/01358 (1997-01-01), None
patent: WO 97/04805 (1997-02-01), None
patent: WO 97/26904 (1997-07-01), None
patent: 97/45550 (1997-12-01), None
patent: WO 99/04026 (1999-01-01), None
patent: WO 99/08692 (1999-02-01), None
patent: 99/18799 (1999-04-01), None
patent: WO 99/18799 (1999-04-01), None
patent: WO 99/29343 (1999-06-01), None
patent: 99/45783 (1999-09-01), None
patent: WO 99/55345 (1999-11-01), None
patent: WO 99/64068 (1999-12-01), None
patent: WO 00/45853 (2000-08-01), None
patent: WO 00/54795 (2000-09-01), None
patent: 00/62735 (2000-10-01), None
Chu et al., The Oncologist, 1996, 1:255-260.
Opponent's Reply of Jan. 2010 in the opposition proceedings of European Patent No. 1 032 269. (German Language).
Opponent's Reply of Jan. 2010 in the opposition proceedings of European Patent No. 1 032 269. (English Translation).
Kawakita, et al., “Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth”, Journal of the Natl Cancer Inst., 89(6):428-36, Mar. 1997.
Hornemann, et al., “Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L”, J. Virol., 77(15): 8394-8407, 2003.
Mullen, “Viral oncolysis”, The Oncologist, 7:106-119, 2002.
Colamonici, et al., Complementation of the interferon α Response in Resistant Cells by Expression of the Cloned Subunit of the interferon α Receptor, The Journal of Biological Chemistry, 269(13): 9598-9602, 1994.
Kolla, et al., “Modulation of Interferon (IFN)-inducible Gene Expression by Retinoic Acid”, The Journal of Biological Chemistry, 271(18): 10508-10514, 1996.
Chen, et al., “Resistance to Interferon of a Human Adenocarcinoma Cell Line, HEC-1, and its Sensitivity to Natural Killer Cell Action”, J. Gen. Virol., 52: 177-181, 1981.
Gomi, et al., “Analysis of Receptors, Cell Surface Antigens, and Proteins in Human Melanoma Cell Lines Resistant to Human Recombinant β- or γ- Interferon”, Cancer Research, 46: 6211-6216, 1986.
Improta, et al., “Interferon-γ Potentiates the Antiviral Activity and the Expression of Interferon-Stimulated Genes Induced by Interferon α in U937 Cells”, Journal of Interferon Research, 12:87-94, 1992.
Meyskens, Jr., “Relation of In Vitro Colony Survival to Clinical Response in a Prospective Trial of Single-Agent Chemotherapy of Metastatic Melanoma”, Journal of Clinical Oncology, 2(11): 1223-1228, 1984.
Morikawa, et al., “Isolation of Human Colon Carcinoma Cells for Resistance to a Single Interferon Associated with Cross-Resistance to Multiple Recombinant Interferons: α, β, and γ”, Journal of the National Cancer Institute, 82(6): 517-522, 1990.
Schiller, et al., “Antiproliferative Effects of Interferons on Human Melanoma Cells in the Human Tumor Colony-Forming Assay”, Journal of Interferon Research, 6: 615-625, 1986.
Izbicka, et al. “Effects of ONYX Adenovirus Preparation on Human Tumor Colony Forming Units”, Proceedings of ASCO; 16:443a, 1997, Abstract 1554.
Mastrangelo, et al., “Poxvirus vectors: orphaned and underappreciated”, The Journal of Clinical Investigation, 105(8): 1031-1034, 2000.
Lee, et al., “Intravesical Gene Therapy: In Vivo Gene Transfer Using Recombinant Vaccinia Virus Vectors”, Cancer Research, 54: 3325-3328, 1994.
Arakawa, Jr., “Clinical trial of attenuated Vaccinia Virus AS strain in the treatment of advanced adenocarcinoma”, J. Cancer Res. Clin. Oncol., 113: 95-98, 1987.
Kawa, et al., “The Effect of Attenuated Vaccinia Virus AS Strain on Multiple Myeloma: A Case Report”, Japan J. Exp. Med.; 57: 79-81, 1987.
Lattime, “In Situ Cytokine Gene Transfection Using Vaccinia Virus Vectors” Seminars in Oncology, 23(1): 88-100, 1996.
Carroll, et al., “Recombinant Vaccinia Virus K3L Gene Product Prevents Activation of Double-stranded RNA-dependent, Initiation Factor 2α-specific Protein Kinase”, The Journal of Biological Chemistry, 268(17): 12837-12842, 1993.
Qin, et al., “Construction of recombinant vaccinia virus expressing GM-CSF and its use as tumor vaccine”, Gene Therapy, 3:59-66, 1996.
Kaufman, et al., A Recombinant Vaccinia Virus Expressing Human Carcinoembryonic Antigen (CEA); Int. J. Cancer, 48: 900-907, 1991.
Ju, et al., “Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a murine melanoma model”, Cancer Gene Therapy, 4(2): 139-144, 1997.
Minutes; Fact and Submissions; and Reason for the Decision in the opposition proceedings of European Patent No. 1032269, Apr. 2010.
Foreign Patent JP 10-5342 (English Language).
Opposition Appeal Brief against European Patent No. 1 032 269, Aug. 2, 2010. (German Language).
Opposition Appeal Brief against European Patent No. 1 032 269, Aug. 2, 2010. (English Language).
Foreign Patent DE3922444 (English Translation), Jan. 10, 1991.
Notice of Opposition to European Patent Application No./Patent No. 98949797.9/1032269 dated Jun. 9, 2008. (English Translation).
Kinderkrebsinfo.de dated May 29, 2008. (English Translation).
Hanson Chapter 7, “Heterogeneity within strains of newcastle disease virus: key to survival ”in Developments in Veterinary Virology, Newcastle Disease edited by D.J. Alexander (Kluwer Academic Publishers) 1998, pp. 113-130.
Spradrow “Epidemiology of Newcastle Disease and the economics of its control”, In processing workshop of poverty eradication and promotion of gender equality Mar. 1999 pp. 171-173.
European Application No. 98949797.9, Response dated Jul. 14, 2005.
Proprietor's Reply to the Opposition
Groene William S.
Lorence Robert M.
Rabin Harvey
Roberts Michael S.
von Borstel Reid W.
Golightly Douglas A.
Kinsey White Nicole
Lucas Zachariah
Wellstat Biologics Corporation
LandOfFree
Infection and treatment of neoplasms with vesicular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Infection and treatment of neoplasms with vesicular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Infection and treatment of neoplasms with vesicular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4282056